Analytical Data
-
Gene name
IGF-I R
-
简介
The IGF-I R protein is a receptor tyrosine kinase that mediates the effects of insulin-like growth factor 1 (IGF1) and has high affinity for IGF1. Upon ligand binding, IGF1R is activated, leading to autophosphorylation and tyrosine phosphorylation of substrates, including IRS1/2, Shc, and 14-3-3 proteins. IGF-I R Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
Biological Activity
1. Immobilized Mouse IGF1R, His Tag at 1 μg/mL (100 μl/well) on the plate. Dose response curve for Human IGFI, hFc Tag with the EC50 of 2.58 μg/mL determined by ELISA. 2.Measured by its binding ability in a functional ELISA. When Recombinant Mouse IGF-I R is immobilized at 5 µg/mL (100 µL/well) can bind Recombinant Human IGF-I. The ED50 for this effect is 322.3 ng/mL. Measured by its binding ability in a functional ELISA. When Recombinant Mouse IGF-I R is immobilized at 5 µg/mL (100 µL/well) can bind Recombinant Human IGF-I. The ED50 for this effect is 322.3 ng/mL.
-
Alternative Names
IGF1R; IGFR; JTK13; CD221; MGC142170; MGC142172; MGC18216
-
Species
Mouse
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by reducing SDS-PAGE.
-
Uniprot
Q60751-1
-
Expression Region
E31-H936
-
AA Sequence
EICGPGIDIRNDYQQLKRLENCTVIEGFLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTIDWSLILDAVSNNYIVGNKPPKECGDLCPGTLEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSVCGKRACTENNECCHPECLGSCHTPDDNTTCVACRHYYYKGVCVPACPPGTYRFEGWRCVDRDFCANIPNAESSDSDGFVIHDDECMQECPSGFIRNSTQSMYCIPCEGPCPKVCGDEEKKTKTIDSVTSAQMLQGCTILKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWNHRNLTVRSGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLRFTSTTTWKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKEGEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPTLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDVEEVTENPKTEVCGGDKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERRRRDVMQVANTTMSSRSRNTTVADTYNITDPEEFETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVPAKTTYENFMH
-
Protein Length
Partial
-
Molecular Weight
110-140 & 50-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like growth factor I receptor (IGF-IR) is a critical transmembrane receptor that mediates the effects of IGF-I, a hormone influencing growth and development in various tissues. The importance of IGF-IR in cellular processes such as proliferation, differentiation, and survival has drawn significant research interest, especially in the context of cancer biology. Aberrant activation of IGF-IR signaling pathways is often associated with various malignancies, making it a potential target for therapeutic interventions. Researchers have been focusing on the development of recombinant IGF-IR proteins to study their structural and functional properties, as well as to facilitate the discovery of IGF-IR inhibitors. These recombinant proteins help in elucidating the receptor's mechanism of action, its interactions with ligands, and downstream signaling pathways. Furthermore, understanding the role of IGF-IR in diseases can lead to the development of targeted therapies, improving treatment strategies for cancer and other IGF-related disorders. The ongoing investigation into recombinant IGF-IR not only enhances our fundamental understanding of cell signaling but also opens new avenues for drug development, potentially leading to more effective treatments in combating diseases associated with IGF-IR dysregulation.











